Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 2

Patient Choice Between Antibiotics and Appendectomy in Uncomplicated Appendicitis (FRENCH 47 - ALACARTE)

NCT07857252 · tracked via the Priya Life Science France tracker
Phase
Phase 2
Started
2026-10
Last updated
2026-10-05

Condition(s) studied

Acute Appendicitis

Investigational drug(s) / intervention(s)

Shared decision-makingamoxicillin-clavulanate →Appendectomy

Shared decision-making: Participants receive standardized information and are then allowed to choose between antibiotic therapy alone and appendectomy. Patients who do not express a preference undergo appendectomy.

amoxicillin-clavulanate: amoxicillin-clavulanate (PO or IV 1 gx3/day for patients \<90 kg or 1 gx4/day for patients ≥90 kg)

Appendectomy: Appendectomy

Study summary

The ALACARTE study evaluates a strategy in which patients with acute uncomplicated appendicitis are given the choice between appendectomy and antibiotic therapy alone. The investigators hypothesize that giving patients the choice of treatment could reduce treatment regret without compromising safety, particularly by not increasing the risk of complicated appendicitis.Treatment regret will be assessed one year after the randomization. A public health benefit is also anticipated through cost reduction, as antibiotic therapy alone is expected to be less costly than surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 18-70 years 2. Diagnosis of uncomplicated AA established by the investigator surgeon that relies on clinico-biological suspicion of acute AA confirm by care radiological tests (US and/or CT and/or MRI) including appendix diameter \>6.0mm. and without: 1. Diffuse peritonitis on clinical exam (i.e., rigid abdomen / four quadrant peritonitis); 2. Radiologic findings of: i. Free air ii. Walled off fluid collection concerning for an abscess iii. Significant amounts of intra-abdominal fluid throughout abdomen (i.e.,more than trace fluid) iv. Extent of inflammation or adjacent organ involvement on radiologic, appendicular plastron on radiologic imaging 3. Surgery expected within 24 hours after diagnosis 4. Patient able to read and understand the language and content of the study documents and agreeing to adhere to the protocol requirements 5. Patient with internet access at home and a valid email address who declares being able to complete an online questionnaire 6. Signature of the written informed consent form by the patient 7. Affiliation to a French health insurance scheme Exclusion Criteria: Exclusion Criteria : 1. Appendicolith visible on radiological tests (US and/or CT and/or MRI) 2. Appendix diameter \>15mm (risk factor of appendicular tumor) visible on radiological tests (US and/or CT and/or MRI) 3. Suspicion of a tumor of the appendix on the imaging exam ((US and/or CT and/or MRI) by the radiologist: (mucocele, pseudomyxoma, neuroendocrine tumor, adenocarcinoma of the appendix, another type of tumor…) 4. Evidence of severe sepsis or septic shock (e.g., new presumed sepsis-related organ dysfunction, elevated lactate, and/or fluid unresponsive hypotension) 5. Severe or uncontrolled comorbidities, such as hepatic cirrhosis, heart failure, acute or chronic kidney failure (estimated glomerular filtration rate \<60mL/min), concurrent hemodialysis or peritoneal dialysis, or treatments using indwelling venous catheters, presence of active cancer or a malignant hemopathy, anticoagulant treatments 6. Recent (within 90 days) placement of surgical implant (e.g., pacemaker, joint prosthesis, mechanical valve) or indwelling Left Ventricular Assist Device 7. Immunodeficiency (e.g., absolute neutrophil count \<500/mm3, chronic immunosuppressive drugs, long term corticosteroids, or known AIDS \[CD4 count \<200/mm3 or AIDS-defining illness assessed by patient history) 8. History of inflammatory bowel disease (Crohn disease, or ulcerative colitis or indeterminate colitis) 9. Ongoing antibiotic therapy for another infection 10. Abdominal/pelvic surgery in the past month 11. Hypersensitivity to Amoxicillin, clavulanic acid and penicillins 12. History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to another beta-lactam (e.g., a cephalosporin, carbapenem, or monobactam). 13. History of icterus/liver damage related to amoxicillin/clavulanic acid 14. Allergy to any of the excipients listed in section 6.1 of SmPC 15. History of AA treated by antibiotics or appendectomy 16. Pregnant\* or breast-feeding women 17. Participation in another interventional study or being in the exclusion period at the end of a previous study. 18. Mental or cognitive impairment rendering the patient unable to understand study information or to provide informed consent. 19. Patient being a relative of the investigator or of a member of the research team directly involved in the trial (assistant doctors, pharmacists, nurses, or study coordinators). 20. Adult under guardianship or deprived of freedom

Primary outcome measure(s)

  • Regret about the initial treatment — 12 month after the randomization
    The presence of regret about the initial treatment will be evaluated through a specific questionnaire completed online by the patient. The question will be: "You were initially treated for your appendicitis (infection of the appendix) either by surgery with removal of the appendix (appendectomy) or by antibiotic therapy alone without surgery initially. Do you regret the treatment you received? YES - NO." The surgeon will be blinded to the answer.

Trial sites (1)

FacilityCityRegionStatus
Department of digestive and general surgery, APHP Saint-Antoine Hospital City Paris Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07857252 on ClinicalTrials.gov ↗ ← All trials in France